![](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/08\/c77e31517dfd08edaa6c551ba0c0ffbd6f542fb2-1200x1200.jpg\"\/)
<\/p>\n<\/p>\n
Primary results of the TITRATE-HF study have shown the importance of early and intensive implementation of guideline-recommended medical therapy (GRMT) and emphasize the need for continuous dose titration to improve heart failure (HF)<\/a> outcomes.<\/p>\n Guidelines for HF currently recommend 4 separate medication classes in patients with reduced ejection fraction. This represents a distinct challenge, particularly in adequately implementing this GRMT, including the timely sequencing of drugs and reaching the target dose. There is currently limited knowledge regarding how the shift from a serial to a parallel approach for drug therapy, specifically the early application of these drug classes, will occur in a clinical setting. To that end, the TITRATE-HF trial was conducted.2<\/p>\n \u201cBy better understanding real-world adherence to GRMT prescription and dosages, as well as the trends in LVEF and clinical outcomes, TITRATE-HF seeks to bridge the gap between clinical guidelines and everyday practice,\u201d wrote Jishnu Malgie, PhD candidate, department of cardiology, Erasmus MC University Medical Center, and colleagues.1<\/p>\n An ongoing observational cohort study conducted across 48 hospitals in the Netherlands from 2022-2024, TITRATE-HF examined guideline adherence and identified barriers to GRMT implementation among patients with HF. Included patients had a confirmed diagnosis with an left ventricular ejection fraction (LVEF) 1<\/p>\n Investigators highlighted 3 separate stages of HF, based on existing definitions: de novo HF, chronic HF, and worsening HF. Worsening HF was described as patients with chronic HF who experienced a related hospitalization or an urgent visit within 6 months prior to enrollment. The study investigated the composite endpoint of all-cause death and HF hospitalization.1<\/p>\n GRMT was defined as the use of renin-angiotensin system inhibitors (RASi), beta-blockers (BB), mineralocorticoid receptor agonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i). Quadruple therapy was defined as the simultaneous use of all 4 drug classes, regardless of dose. A GRMT log was maintained for each patient, beginning at the time of diagnosis for de novo HF or of study inclusion for chronic and worsening HF, as well as a 6-month follow-up.1<\/p>\n A collective 3367 patients were enrolled and stratified into the 3 HF categories. 1508 exhibited de novo HF, 1603 had chronic HF, and 256 were categorized as worsening HF. Median ages were 70 (interquartile range [IQR] 62-77), 72 (IQR 63-78), and 74 years (IQR 67-79), respectively. A total of 64%, 50%, and 45% of patients had non-ischemic cardiomyopathy (CMP), respectively.1<\/p>\n Quadruple therapy was prescribed to 47.2% of the de novo group at 6 weeks, 64.7% at 3 months, 69.5% at 6 months, and 64.4% at 12 months. It was prescribed to 44.6% of the chronic and worsening groups at baseline, 53.7% at 6 months, and 54.6% at 12 months. These increases were largely driven by greater SGLT2i uptake.1<\/p>\n Patients with de novo HF who were given serial echocardiograms (n = 752), median LVEF improved by 10% in ischemic versus 15% in non-ischemic cardiomyopathy (P 1<\/p>\n At 12 months, the composite endpoint had occurred in 13.3%, 13.3%, and 43.8% of the de novo, chronic, and worsening groups, respectively. An unadjusted Cox regression analysis showed a substantially higher risk of reaching the endpoint after discontinuation or down-titration (hazard ratio [HR] 1.88; 95% CI, 1.5-2.35; P P 1<\/p>\n \u201cAlthough GRMT prescription rates in TITRATE-HF were relatively high compared to previous HF registries, substantial room for improvement remains,\u201d Malgie and colleagues wrote. \u201cEach patient contact should be approached with a sense of urgency for continuous GRMT up-titration and as an opportunity to improve guideline adherence.\u201d1<\/p>\n References<\/p>\n\n